551 related articles for article (PubMed ID: 23321417)
1. Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia.
Liao R; Xu Y; Chen M; Chen X; Zhan X; Sun J
Hematology; 2013 Jul; 18(4):191-7. PubMed ID: 23321417
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
3. [Research progress on mechanism of MDS transformation into AML].
Wang LL; Gao C; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
[TBL] [Abstract][Full Text] [Related]
4. Deregulated microRNA expression and its pathogenetic implications for myelodysplastic syndromes.
Kuang X; Chi J; Wang L
Hematology; 2016 Dec; 21(10):593-602. PubMed ID: 27357100
[TBL] [Abstract][Full Text] [Related]
5. Implication of microRNAs in the pathogenesis of MDS.
Fang J; Varney M; Starczynowski DT
Curr Pharm Des; 2012; 18(22):3170-9. PubMed ID: 22571695
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia.
Guo Y; Strickland SA; Mohan S; Li S; Bosompem A; Vickers KC; Zhao S; Sheng Q; Kim AS
Leuk Lymphoma; 2017 Sep; 58(9):1-15. PubMed ID: 28084850
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndrome hematopoietic stem cell.
Li J
Int J Cancer; 2013 Aug; 133(3):525-33. PubMed ID: 23047726
[TBL] [Abstract][Full Text] [Related]
8. DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.
Ozdogan H; Gur Dedeoglu B; Oztemur Islakoglu Y; Aydos A; Kose S; Atalay A; Yegin ZA; Avcu F; Uckan Cetinkaya D; Ilhan O
Leuk Res; 2017 Dec; 63():62-71. PubMed ID: 29102598
[TBL] [Abstract][Full Text] [Related]
9. Innate immune signaling in the myelodysplastic syndromes.
Starczynowski DT; Karsan A
Hematol Oncol Clin North Am; 2010 Apr; 24(2):343-59. PubMed ID: 20359630
[TBL] [Abstract][Full Text] [Related]
10. Deregulation of microRNAs in myelodysplastic syndrome.
Rhyasen GW; Starczynowski DT
Leukemia; 2012 Jan; 26(1):13-22. PubMed ID: 21852786
[TBL] [Abstract][Full Text] [Related]
11. FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome.
Schieber M; Marinaccio C; Bolanos LC; Haffey WD; Greis KD; Starczynowski DT; Crispino JD
Blood Cancer J; 2020 Oct; 10(10):98. PubMed ID: 33024076
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
Bernasconi P
Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
[TBL] [Abstract][Full Text] [Related]
13. Clonality studies and N-ras and p53 mutation analysis of hematopoietic cells in Fanconi anemia.
Venkatraj VS; Gaidano G; Auerbach AD
Leukemia; 1994 Aug; 8(8):1354-8. PubMed ID: 8057673
[TBL] [Abstract][Full Text] [Related]
14. Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins.
Bauer M; Vaxevanis C; Heimer N; Al-Ali HK; Jaekel N; Bachmann M; Wickenhauser C; Seliger B
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992663
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation.
Hospital MA; Vey N
Curr Oncol Rep; 2020 Jan; 22(1):4. PubMed ID: 31974774
[TBL] [Abstract][Full Text] [Related]
16. Molecular bases of myelodysplastic syndromes: lessons from animal models.
Komeno Y; Kitaura J; Kitamura T
J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
[TBL] [Abstract][Full Text] [Related]
17. miRNAs in acute myeloid leukemia.
Liao Q; Wang B; Li X; Jiang G
Oncotarget; 2017 Jan; 8(2):3666-3682. PubMed ID: 27705921
[TBL] [Abstract][Full Text] [Related]
18. What biologic factors predict for transformation to AML?
Bejar R
Best Pract Res Clin Haematol; 2018 Dec; 31(4):341-345. PubMed ID: 30466744
[TBL] [Abstract][Full Text] [Related]
19. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
[TBL] [Abstract][Full Text] [Related]
20. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
